On September 1, 2026, Kazia Therapeutics announced preclinical data demonstrating that its lead asset, paxalisib, reduced tumor burden by 52% in microsatellite stable (MSS)/proficient mismatch repair (pMMR) colorectal cancer models and enhanced response to immunotherapy. The company plans to launch a five-arm Phase 2 clinical trial for this indication, with enrollment expected to begin in the first quarter of 2027. Additionally, Kazia reported preclinical evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors in HR+/HER2- breast cancer models and announced an expansion of its ongoing triple-negative breast cancer trial to include a three-arm evaluation of paxalisib combinations in this population. First patient enrollment for the breast cancer expansion is targeted before year-end 2026, with full enrollment anticipated by the end of 2027. Kazia Therapeutics operates as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology and restore anti-tumor immunity.
